Sign in
Taking people in United StatesPhase 1/2

Tests donor immune cells with chemotherapy for relapsed or resistant blood cancers

Tests donor natural killer cells with chemotherapy in people with blood cancers.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Status
Recruiting
Phase
Phase 1/2
People taking part
80 people, planned
Started
1 Nov 2022
Expected to end
31 Aug 2030
Type of study
Interventional, 3 groups
Treatments tested
  • Cyclophosphamide
  • CAR.70/IL15-transduced CB-NK cells
  • Fludarabine phosphate
Record updated
7 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 to 80 with a blood cancer that has come back or not responded to treatment, and whose tumor cells carry the CD70 marker. It tests NK cells given with chemotherapy.

Age
12 to 80 years, and weight of at least 40 kg (88 lb).
Sex
All sexes can join.
Disease stage
Blood cancers such as leukemia, lymphoma or multiple myeloma, that came back or did not respond to treatment. The person must also meet disease-specific criteria, which are not listed in the record.
Earlier treatment
At least 1 week since the last chemotherapy before lymphodepleting chemotherapy starts. Hydroxyurea is allowed until the day before. Tyrosine kinase inhibitors or other targeted therapies can continue until 3 days before. Localized radiotherapy is allowed if other disease sites are not irradiated.
Biomarker or test result
CD70 in at least 10% of the tumor sample, measured by immunohistochemistry or flow cytometry.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • HIV with a detectable viral load
  • Uncontrolled infection that is not responding to treatment
  • Active graft-versus-host disease needing treatment, or stem cell transplant or DLI less than 12 weeks before chemotherapy
  • Another active cancer, other anti-cancer or investigational drugs, or immunosuppressive therapy

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Patients with hematological malignances with an expression of CD70 in the pre-enrollment tumor sample ≥ 10% measured by immunohistochemistry or flow cytometry
  • Patients must meet diseases specific eligibility criteria (see below)
  • Patients at least 1 week from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy, except for Hydroxyurea which is allowed for peripheral blood count control in AML, CML, and MDS patients until the day prior to administration of lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until up to three days prior to administration of lymphodepleting chemotherapy
  • Localized radiotherapy to one or more disease sites is allowed prior the infusion provided that there are additional disease sites that are not irradiated to assess response
  • Karnofsky Performance Scale > 50% for patients who are >16 years old or Lansky score ≥50% for patients who are ≤16 years of age
  • Adequate organ function:; Renal: Serum creatinine </= 2x ULN or estimated Glomerular Filtration Rate >/= 30 ml/min/1.73 m2; Hepatic: ALT/AST </= 3 x ULN or </= 5 x ULN if documented liver metastases, Total bilirubin </2xULN, except in subjects with Gilbert's Syndrome in whom total bilirubin must be </= 3 x.ULN. No history of liver cirrhosis. No ascites; Cardiac: Cardiac ejection fraction >/= 40%, no clinically significant pericardial effusion as determined by an ECHO, and no uncontrolled arrhythmias or symptomatic cardiac disease; Pulmonary: No clinically significant pleural effusion (per PI discretion), baseline oxygen saturation > 92% on room air and adequate pulmonary function with FEV1, FVC and DLCO (corrected for Hgb) >50%
  • Able to provide written informed consent
  • 12-80 years of age
  • Weight ≥40 kg
  • All participants who are able to have children must practice effective birth control while on study and up to 3 months post completion of study therapy. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor
  • Signed consent to long-term follow-up protocol PA17-0483 to fulfill the institutional responsibilities to various regulatory agencies
  • Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative [LAR])

Who cannot take part

  • Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females
  • Presence of clinically significant Grade 3 or greater toxicity from the previous treatment, as determined by PI
  • Active (defined as requiring therapy) acute or chronic GVHD
  • Major surgery <4 weeks prior to first dose of the preparatory chemotherapy
  • Allogeneic SCT or DLI <12 weeks prior to first dose of preparatory chemotherapy
  • Concomitant use of other investigational agents
  • Concomitant use of other anti-cancer agents
  • Patients receiving immunosuppressive therapy
  • Presence of uncontrolled fungal, bacterial, viral, or other infection not responding to appropriate therapy
  • HIV with detectable viral load
  • Presence of active neurological disorder(s)
  • Active autoimmune disease within 12 months of enrollment
  • Amyloidosis or POEMS syndrome
  • Active cerebral or meningeal involvement by the malignancy
  • Any other malignancy known to be active, except for treated cervical intra-epithelial neoplasia and non-melanoma skin cancer
  • Presence of any other serious medical condition that may endanger the patient at investigator discretion
  • Patients receiving systemic steroid therapy at time of NK cell infusion (physiological substitutive doses are allowed), or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 80 years old?

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesContact: David Marin, MDTaking people

About the trial

What the trial wants to find out

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.

Read full original descriptionShow less

Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.

The 3 groups in the trial

  • CyclophosphamideTreatment being tested

    Cyclophosphamide is dosed per adjusted body weight for patients weighing \> 20% above their ideal body weight using the calculation.

    Treatment: Cyclophosphamide and Fludarabine phosphate

  • CAR.70/IL15-transduced CB-NK cellsTreatment being tested

    Patients will receive a single flat dose of CAR-NK.

  • Fludarabine phosphateTreatment being tested

    Fludarabine is dosed using actual body weight.

    Treatment: Cyclophosphamide and Fludarabine phosphate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Plain-language title
Tests donor immune cells with chemotherapy for relapsed or resistant blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05092451, who can take part
Publications
Record updated
7 August 2026